January 5, 2022 – The CDC Advisory Commission today recommended that 12- to 17-year-olds in the United States be vaccinated with the Pfizer COVID-19 supplementary vaccine 5 months after the primary vaccination series.
The CDC has already said that 16- and 17-year-olds “can” get a Pfizer booster, but today’s recommendation adds a group of 12-15 and stronger “laughs” to “should” for 16- and 17-year-olds.
The committee voted 13-1 to recommend a supplementary drug for ages 12-17.
Voting comes after the FDA authorized by Pfizer on Monday additional dose of vaccine for children 12 to 15 years.
The FDA action has updated the authorization for the Pfizer vaccine, and the agency has also shortened the recommended time between the second dose and the supplemental dose to 5 months or more (by 6 months). A third primary batch of doses has also now been safely approved immunocompromised children between 5 and 11 years. All details are available at FDA news release.
The CDC on Tuesday also supported a shortened time frame and a third primary dose series for some immunocompromised children ages 5 to 11. But the CDC has postponed a decision to supplement the drug for children ages 12 to 15 until an advisory committee on immunization practice is announced today.
The decision came at a time when school districts across the country are struggling to decide whether to keep schools open or return to a virtual format as the number of cases grows, and as a pediatric The number of COVID-19 cases and hospitalizations is reaching new heights.